Stay updated with the latest information on Lecanemab and join our patient webinars for additional details on eligibility criteria, side effects, infusion protocols, safety monitoring, and cost.

0 views • 6 slides

The MGB Alzheimer Therapeutics Program is a collaborative effort leading to groundbreaking disease-modifying therapies for Alzheimer's disease. The development of Lecanemab (Leqembi), a monoclonal antibody targeting amyloid plaques, offers a new option to slow disease progression. The program's focu

0 views • 21 slides